SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ryan Weisman who wrote (587)12/5/1997 7:08:00 AM
From: Steven Zimmer  Read Replies (2) of 1894
 
Ryan

I believe that you are only partially right. While it is true that ACMI has something to prove to the world and that Peter Gombrich's selling does not help the Company in perception terms, it is also the case that Cytc's news is not bad news for ACMI in the least. CYTC's Thin Prep is a front end device to ACMI's semi-automated system and ACMI now has data to show that its system actually enhances the reading of CYTC's Thin Prep samples and lowers the overall cost per test to the Lab. My belief (backed by buying at these prices!) is that the combination of CYTC's sample preparation and ACMI's recently acquired deal with a finance company to finance placements of ACMI systems, will prove to be powerful incentives to the cytopath lab to convert to such a system. The recent HCFA announcement will enhance and facilitate this process and ACMI's Sales and Marketing restucturing together with the announced cost savings, set the stage for a 1998 which should finally yield the prospects that investors have been looking for for some time. By the way, P.B.'s selling of stock has nothing to do with the prospects of the company and all to do with personal needs; this I know for a fact!. Use the tax selling period to accumulate the stock!

Greetings

Steven
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext